title: 1,3,7-trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism.
abstract: The genetic elimination of A2A adenosine receptors (A2AR) was shown to disengage the critical immunosuppressive mechanism and cause the dramatic exacerbation of acute inflammatory tissue damage by T cells and myeloid cells. This prompted the evaluation of the proinflammatory vs the anti-inflammatory effects of the widely consumed behavioral drug caffeine, as the psychoactive effects of caffeine are mediated largely by its antagonistic action on A2AR in the brain. Because caffeine has other biochemical targets besides A2AR, it was important to test whether the consumption of caffeine during an acute inflammation episode would lead to the exacerbation of immune-mediated tissue damage. We examined acute and chronic treatment with caffeine for its effects on acute liver inflammation. It is shown that caffeine at lower doses (10 and 20 mg/kg) strongly exacerbated acute liver damage and increased levels of proinflammatory cytokines. Because caffeine did not enhance liver damage in A2AR-deficient mice, we suggest that the potentiation of liver inflammation was mediated by interference with the A2AR-mediated tissue-protecting mechanism. In contrast, a high dose of caffeine (100 mg/kg) completely blocked both liver damage and proinflammatory cytokine responses through an A2AR-independent mechanism. Furthermore, caffeine administration exacerbated liver damage even when mice consumed caffeine chronically, although the extent of exacerbation was less than in "naive" mice that did not consume caffeine before. This study suggests an unappreciated "man-made" immunological pathogenesis whereby consumption of the food-, beverage-, and medication-derived adenosine receptor antagonists may modify an individual's inflammatory status and lead to excessive organ damage during acute inflammation.
authors.affiliation: New England Inflammation and Tissue Protection Institute at Northeastern University, Boston, MA 02115, USA. a.ohta@neu.edu
authors.forename: Akio
authors.initials: A
authors.lastname: Ohta
authors.forename: Dmitriy
authors.initials: D
authors.lastname: Lukashev
authors.forename: Edwin K
authors.initials: EK
authors.lastname: Jackson
authors.forename: Bertil B
authors.initials: BB
authors.lastname: Fredholm
authors.forename: Michail
authors.initials: M
authors.lastname: Sitkovsky
mesh_terms: D036002:ADP Ribose Transferases; D000208:Acute Disease; D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D001427:Bacterial Toxins; D002110:Caffeine / Q000097:blood / Q000633:toxicity*; D056486:Chemical and Drug Induced Liver Injury / Q000276:immunology* / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005098:Exotoxins; D005260:Female; D008099:Liver / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010726:Phosphodiesterase Inhibitors / Q000097:blood / Q000633:toxicity; D043705:Receptor, Adenosine A2A / Q000235:genetics / Q000276:immunology*; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
chemical_list: D036002:ADP Ribose Transferases; D058917:Adenosine A2 Receptor Antagonists; D001427:Bacterial Toxins; D002110:Caffeine; D005098:Exotoxins; D010726:Phosphodiesterase Inhibitors; D043705:Receptor, Adenosine A2A; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A